Risk factors for progression to acute respiratory failure after casirivimab and imdevimab administration: A retrospective study

BACKGROUND: Casirivimab and imdevimab are effective in preventing hospitalization in outpatients with coronavirus disease 2019 (COVID-19); however, disease progression after casirivimab and imdevimab administration has been reported. This study aimed to elucidate the risk factors for disease progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Noriaki, Kitahara, Yoshihiro, Miwata, Kei, Okimoto, Mafumi, Takafuta, Toshiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Respiratory Society. Published by Elsevier B.V. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110271/
https://www.ncbi.nlm.nih.gov/pubmed/35589514
http://dx.doi.org/10.1016/j.resinv.2022.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110271/
https://www.ncbi.nlm.nih.gov/pubmed/35589514
http://dx.doi.org/10.1016/j.resinv.2022.04.005

Ejemplares similares